Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Melacine: Phase III data; marketed in Canada

CRXA said that its Phase III trial of Stage II melanoma patients who received Melacine or observation alone following surgical removal of their tumors did not show

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE